AEROECLIPSE*

Rationale

Posted in Presented Research, Published Studies, Aerobika*, AEROECLIPSE*

In vivo study showing deposition outcomes with scintigraphy for neb alone or neb plus OPEP
RESULT: Combining neb plus OPEP offers the potential for optimal combined therapy.

Poster Discussion Presentation: Tuesday 01 October: 12:50 - 14:40
Session 461, TP-31
Poster PA4529

Posted in Presented Research, Published Studies, AEROECLIPSE*

Presented at ATS 2019:

  • This study has shown there is a relatively linear association of airway pressures with increase in gas flow when using the device over the gas flows investigated.
  • The VersaPAP* device could be considered to provide short-term positive pressure support to a patient if there was no direct access to the use of non-invasive mechanical ventilation.

Download poster

Posted in Published Studies, Presented Research, ATS, AEROECLIPSE*

Presented at ATS 2019:

  • The MC 300* nebulizer offers the clinician additional choice when short treatment times and maximizing respirable dose are a priority.

Download poster

Posted in Presented Research, Published Studies, ATS, AEROECLIPSE*

Poster presented at ERS 2018 in Paris, France

A new ERS Technical Standard was published in 2017, providing guidance on how to perform the Methacholine Challenge Test (MCT), incorporating a change from evaluating the Provocative Concentration to the Provocative Dose (PD20).

Download poster

Posted in Published Studies, Presented Research, ERS 2018, AEROECLIPSE*

This study compared a continuous jet nebulizer (MMC Continuous, in development), with other continuous jet nebulizers available in the USA.

Download poster

Posted in Published Studies, Events, Presented Research, AEROECLIPSE*, ATS

Chronic Obstructive Pulmonary Disease (COPD) is a significant healthcare problem, with an estimated 384 million cases worldwide in 2010.1 Population aging is predicted to drive further growth, with one study forecasting a 150% increase in prevalence overall, and up to 220% in the 75 and over age group, between 2010 and 2030.

Posted in Press, News, COPD, AeroCount*, AEROECLIPSE*

The AeroEclipse* II BAN is the most significant advancement in the history of small volume nebulizers, generating aerosol only in response to the patient's inspiratory maneuver. Since virtually no aerosol is produced during exhalation or at rest, clinicians can be confident that the dose prescribed is the dose delivered.

Posted in Published Studies, AEROECLIPSE*, COPD